Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q3 2021 Earnings Presentation
20 slides from Bactiguard Holding Ab's earnings presentation, Oct 28, 2021
Slide 1: Investor presentation Q3 2021
Investor presentation Q3 2021 28 October, 2021 Anders Göransson, CEO Gabriella Björknert Caracciolo, CFO
Slide 2: Bactiguard
Bactiguard Infection prevention – Saving lives 2
Slide 3: Anders Göransson, CEO
Anders Göransson, CEO October 1st, 2021 Background: • Various management positions within Amgen, a leading biotech company • Broad consulting experience from McKinsey and Ernst & Young Education: • MSc in Business, Uppsala, SE • MBA, Suffolk University, USA 3 3
Slide 4: Chief Licensing Officer - strengthening the management and licensing team
Chief Licensing Officer - strengthening the management and licensing team October 1st, 2021 Background: • Various positions in leading pharma and MedTech companies, Glaxo Smith Kline, Janssen, Mundipharma and Mölnlycke. • CEO of Ortho Center and Sales and Marketing Director at Aleris Education: • MB
Slide 5: Bactiguard – third quarter 2021
Bactiguard – third quarter 2021 Key Financials, Q3 2021 (Q3 2020) Sales EBITDA Net Profit Operating cash flow MSEK 45.2 (34.2) • License 30.1 (20.2) MSEK 1.2 (-3.1) MSEK -10.8 (-16.1) MSEK 14.3 (-3.3) • BIP sales 13.2 (10.4) Directed new share issue to AMF, of SEK 228 million 1,500,000 B shares at a
Slide 6: Business Highlights – third quarter 2021
Business Highlights – third quarter 2021 BD business recovering, ZNN Bactiguard launch and Wound care rollout LICENSE BUSINESS BACTIGUARD PORTFOLIO • BD business recovering to pre-covid • Exploring joint promotion with ZB levels • Aniocyn - veterinary care available • Zimmer® Natural Nail® (ZNN) in
Slide 7: Zimmer Biomet Bactiguard launch
Zimmer Biomet Bactiguard launch EMEA launch
Slide 8: Increased focus on commercialisation
Increased focus on commercialisation Well positioned for the next phase • Positive impact from the Customer / Patient investments in our own sales forces • Strengthening our distributor network and management Own sales force Distributor Bactiguard / Distributor • Leveraging our ‘Bactiguard Service S
Slide 9: Global outlook
Global outlook Covid-19 situation by WHO • Over 240 million cases • App. 5 million deaths • In general the increase in vaccination rates is reducing the number of Covid- 19 cases − In Malaysia 95% of the adult population is fully vaccinated • EU – increasing infection rates especially in eastern Eur
Slide 10: COVID and Hospital Acquired Infections (HAI)
COVID and Hospital Acquired Infections (HAI) The pandemic shows the importance of infection prevention • Recent publication from US Center for Disease Control and Prevention (CDC) • NHSN (national healthcare safety network) – HAI surveillance system • Quarterly data from 2020 compared with 2019 • In
Slide 11: VITAL study
Studies to commercialize… VITAL study VAP* reduction in ICU by Bactiguard coated endotracheal tubes Topline results presented in award winning presentation at ESICM • Randomized, controlled study on ICU patients, Liège, Belgium • Safety: no adverse events related to the coating Time to VAP, Kaplan-M
Slide 12: Malaysian Operations
Malaysian Operations Bactiguard facilities in Malaysia 12
Slide 13: Financial update
Financial update 13
Slide 14: Stable third quarter revenues
Stable third quarter revenues Still negative COVID-19 impact on the business • BD license revenue increase in Q3 and stabilised on a yearly basis despite negative currency effect • BIP revenues still negatively affected by Covid-19 • Newly signed wound care partnerships first revenues in Q3 • New li
Slide 15: Financial overview
Financial overview • Higher license revenue Q3 resulted in: - Revenue growth of 32%, and . organic revenue growth of . 36%, resulting in MSEK 45.2 - EBITDA of MSEK 1.2 (-3.1) . with an EBITDA-margin of 3% (-9%). Clear improvement vs . Q3 2020 • EBITDA YTD lower than previous year due to extraordinar
Slide 16: Cash flow and liquidity
Cash flow and liquidity • New share issue of MSEK 228 before transaction cost • Q3 positive operating cash flow of MSEK 14.3 (-3.3) • Overdraft facility unutilized, compared to September 30, 2020 MSEK (16.1) • Available liquidity MSEK 280.5 incl. overdraft facility Cash and cash Cash flow from Overd
Slide 17: Bactiguard – My reflections
Bactiguard – My reflections Well positioned to move to the next phase My reflections "I am proud and energized to lead • Infection prevention more important than ever Bactiguard in this exciting phase of the company's development! • Bactiguards unique coating has a key role to play We are now invest
Slide 18: Bactiguard on the outside – safe on the inside
Bactiguard on the outside – safe on the inside 18 18
Slide 19: Questions & Answers
Questions & Answers Anders Göransson Gabriella Björknert Caracciolo CEO CFO +46 8 440 58 80 +46 8 440 58 80 anders.goransson@bactiguard.com gabriella.caracciolo@bactiguard.com 19
Slide 20: Upcoming events and financial reports
Upcoming events and financial reports February 10, 2022 • Year-end report, 2021 20